Abstract: Mismatch repair (MMR) deficiency in solid tumors has recently been linked to susceptibility to immunotherapies targeting the programmed cell death-1 (PD-1)/programmed cell death-1 ligand (PD-L1) axis. Loss of MMR proteins has been shown to correlate with tumoral PD-L1 expression in colorectal and endometrial carcinomas, but the association between expression of MMR proteins and PD-L1 has not previously been studied in breast carcinoma, where MMR deficiency is less common. We assessed the relationship between PD-L1 and MMR protein expression by immunohistochemistry in 245 primary and 40 metastatic breast carcinomas. Tumoral staining for PD-L1 was positive in 12% of all cases, including 32% of triple-negative cancers. MMR deficiency was observed in 0.04% of breast cancers; the single MMR-deficient case was a high-grade, triplenegative ductal carcinoma which showed dual loss of MLH1 and PMS2 proteins and expressed PD-L1. Two ER + carcinomas initially were scored with MMR protein loss in tissue microarray format but were subsequently shown to be MMR-intact on whole sections. Analysis of MMR gene mutation in The Cancer Genome Atlas corroborates low frequency of MMR deficiency for invasive breast cancer. MMR protein expression is therefore unlikely to show utility as a screen for immunotherapeutic vulnerability in this tumor type, and may provoke unwarranted genetic testing in patients unlikely to have a heritable cancer syndrome. PD-L1 may be a more clinically relevant biomarker for anti-PD-1/PD-L1 therapies in this setting.
BACKGROUND
Immunotherapy has been hailed as a panacea for cancer, but evidence suggests that it works only a fraction of the time and only on a subset of tumors. [1] [2] [3] [4] [5] [6] Informed candidate selection is therefore critical to ensure that these drugs are given to the patients most likely to respondand that patients unlikely to benefit are not subjected to unnecessary cost, risk, and morbidity. 1 One of the most promising immunotherapeutic mechanisms centers on the programmed cell death-1 (PD-1) pathway. 4, 7, 8 PD-1 functions in healthy tissues as a checkpoint in the immune response, interacting with its ligands (PD-L1 and PD-L2) to suppress cytotoxic T-cell activity and stimulate regulatory T-cell development, thereby preventing immunopathology secondary to persistent inflammation. 9 This instrument of immune tolerance becomes problematic, however, when PD-L1 is expressed by tumor cells, either in response to inflammation or by oncogenic processes leading to evasion from effector immune cells. 9 Immunotherapies targeting PD-1 and PD-L1 uncloak tumors and expose them to immune surveillance and attack. 3, 5, 10 Some data have suggested that immunohistochemical expression of PD-L1 in tumor cells provides the best predictor of response to anti-PD-1/anti-PD-L1 therapies across a variety of tumors. 3 However, the threshold of staining required for response is inconsistent, and PD-L1 immunohistochemistry studies have been troubled by variability across antibody clones. [11] [12] [13] [14] More recent evidence indicates that mismatch repair (MMR) deficiency (and the microsatellite instability that attends it) could provide a robust marker for anti-PD-1/anti-PD-L1 response. A strong correlation between PD-L1 expression and MMR deficiency has been demonstrated in colorectal and endometrial carcinomas, [15] [16] [17] and susceptibility to PD-1/PD-L1 inhibition has been documented in MMR-deficient tumors from these locales. 18 Robust therapeutic responses have also been demonstrated in a broader trial in MMR-deficient cancers that includes 12 tumor types, however breast carcinoma was notably absent from that study. 19 Furthermore, MMR deficiency is extremely rare in breast cancers (< 1%). 19, 20 Despite the rarity of MMR deficiency in breast carcinomas, MMR testing is being ordered with increasing frequency in these tumors due to the recent Food & Drug Administration approval of pembrolizumab in all cancers with MMR deficiency. Given that the approval was based on data that was not derived from breast carcinomas, there are 3 potential drawbacks with this testing approach: (1) that the expense of MMR or microsatellite instability testing (which involve 4 immunohistochemical stains and a molecular test, respectively) may be difficult to justify given the rarity of the genetic defect in tumors from this site; (2) that MMR-based screening alone may miss breast cancer patients who may benefit from anti-PD-1/PD-L1 therapy; (3) that MMR testing in breast cancer may lead to unwarranted genetic counseling referrals and testing in patients highly unlikely to have Lynch syndrome (a primary cause of MMR deficiency).
Prior work from our institution has identified tumoral PD-L1 expression by immunohistochemistry in 12% of all breast cancers including over 30% of triplenegative carcinomas, and extrapolation from other organs suggests that these PD-L1
+ tumors may respond to inhibition targeting the PD-1/PD-L1 axis. 3, 21 We herein evaluate a large cohort of breast cancer cases for MMR expression to determine the relationship between PD-L1 expression and MMR status, and assess whether this relationship can inform testing for cost-effective identification of immunotherapeutic candidates.
MATERIALS AND METHODS
This study was approved by the institutional review board of The University of Virginia.
Case Selection and Tissue Microarray Construction
Cases were evaluated on 4 tissue microarrays (TMAs) containing archival formalin-fixed, paraffin-embedded tissues from 245 invasive primary breast carcinomas, 20 nodal metastases, and 20 distant metastases. Control tissues from kidney, liver, and placenta were also present. The arrays contained 4 replicate 0.6 mm cores from each case with samplings from different areas within the original tumor section including the tumor periphery and center.
The arrays contained a range of tumor stages and histologic subtypes. All primary tumors and all nodal metastases represented on the TMAs were treatment-naive. Seventeen of 20 distant metastases occurred after primary resection and therapy (mean time since primary diagnosis: 4.5 y); 3 were identified at the time of primary diagnosis and were treatment-naive. Sixteen of the nodal metastases and 1 lung metastasis were matched to concurrent primary tumors also present on the arrays: all matched cases were treatment naïve in both locales.
Clinicopathologic information including tumor histologic type, grade, stage, hormone receptor status, and patient age was obtained on all cases. Germline BRCA mutation status was obtained whenever possible.
Immunohistochemistry

Programmed Cell Death-1 Ligand
Immunohistochemical staining for PD-L1/CD274 (SP142, rabbit IgG, catalog # M4420; Spring Bioscience, Pleasanton, CA) was performed on all TMAs using the Leica Bond III platform. This antibody has been previously calibrated and validated in our laboratory on a large array of non-small cell lung carcinomas against results obtained on the Dako 22C3 antibody using the Dako platform with satisfactory results (eg, no discrepant cases at clinically relevant thresholds).
PD-L1 immunohistochemistry was read by A.M.M. and E.A.D at a dual head microscope. PD-L1 immunohistochemical staining was classified as positive when clear membranous staining was present in ≥ 1% of tumor cells. The 1% threshold for positivity was selected based on data demonstrating clinical response to PD-L1 inhibition at this expression level in some cancers, and percentage categories were further selected to include the cutoffs for all available PD-L1 inhibitors. 1, 3 Staining extent was further characterized in the following subcategories: 1% to 5%, 6% to 10%, 11% to 25%, 26% to 50%, and > 50%. Detailed PD-L1 immunohistochemical staining results on this cohort were previously reported in detail in a previous study. 21 
MMR Proteins
MMR protein immunohistochemistry was read by A.M.M. MMR deficiency was diagnosed when there was complete loss of tumoral nuclear immunostaining for MLH1 (clone ES05, predilute; Leica Biosystems), PMS2 (clone MRG-28Mab, predilute; Cell Marque), MSH2 (clone 25D12, predilute; Leica), and/or MSH6 (clone 44 Mab, predilute; Cell Marque) in the setting of intact control stromal/lymphocyte staining. MMR protein loss identified on tissue microarray was confirmed on whole section slides.
The Cancer Genome Atlas Public Data Set Analysis
The Cancer Genome Atlas (TCGA) is a project by the National Cancer Institute's Center for Cancer Genomics. The publicly available TCGA repository includes gene expression profiling, copy number variation profiling, SNP genotyping, DNA methylation profiling, microRNA profiling, and exon sequencing of over 1200 genes in 33 tumor types. Analysis of the publicly available TCGA database was performed using the ebioportal link (www. cbioportal.org/) and the following search criteria for mutation and expression: invasive breast cancer, MLH1, MSH6, MSH2, PMS2. Comparison of mutation/ expression rates were performed for colorectal adenocarcinoma and uterine adenocarcinoma and displayed graphically.
RESULTS
PD-L1 Expression
PD-L1 expression for the UVA microarray cohort is described in detail in a prior publication. 21 Briefly, PD-L1 was expressed by tumor cells in 12% of all cancers in this series, including 32% (18/57) of triple-negative cancers. Two of 4 hormone receptor-negative, HER2-amplified cancers were also PD-L1 + . In contrast, only 5% (9/181) of hormone receptor-positive cancers expressed PD-L1 (HER2 amplification status was unavailable for 3 cases therefore these were excluded from analysis). PD-L1 expression was most common among grade 3 tumors, 31% (25/82) of which were positive (vs. 4% [2/51] of grade 1 and 3% [2/112] of grade 2 tumors). PD-L1 expression was not significantly correlated with stage, and was not more frequently observed in either nodal or distant metastases when compared with matched primary tumors. Half (3/6) of tumors with known BRCA mutations were PD-L1 + , however this expression rate was not significantly higher than for triple-negative, BRCA-wildtype cancers (P = 1).
MMR Protein Expression
MMR protein loss was observed in 3 cases on TMA: 1 triple-negative, high-grade ductal primary carcinoma (case 1) and 2 estrogen receptor (ER) + metastases: 1 lung metastasis (case 2) and 1 lymph node metastasis (case 3) ( Fig. 1 and Table 1 ). Neither of the metastatic cases had matched primaries present on the TMA. BRCA mutation status was unknown for all 3 cases, and none of the patients had a significant family or personal cancer history. Whole section staining of case 1 demonstrated total loss of MLH1 and PMS2 throughout the tumor, confirming MMR deficiency. The 2 estrogen receptorpositive cases were negative for MSH2 and MSH6 on tissue cores represented on the TMA, however whole sections revealed focal positivity for these markers, excluding complete MMR deficiency. (Fig. 2 and Table 1 ) Additional, whole sections from the primary tumor for case 3 were also MMR-intact; primary material original was not available for case 2.
Relationship Between PD-L1 and MMR Protein Immunohistochemistry
The single MMR-deficient case showed focal tumoral staining for PD-L1 (1% to 5% of cells) (Fig. 1 ). In addition, there was robust associated immune cell (lymphocyte and macrophage) expression of PD-L1. The 2 ER + cases which showed MMR loss on cores but which were confirmed to be MMR-intact on whole sections were entirely negative for PD-L1 in both the tumor cells and in the immune compartment. All remaining PD-L1 + cases in the study were MMR-intact, including cases with strong diffuse positivity (Fig. 3) .
MMR Gene Mutation and Protein Expression in TCGA Database
In the invasive breast cancer set of 963 cases in TCGA, 2.9% of cases demonstrated any mutation in at least one of the 4 MMR genes (MLH1, PMS2, MSH2, and MSH6) and 2.3% demonstrated amplification. 22, 23 As Figure 5 shows, the majority of mutations in breast cancer cases in TCGA were passenger mutations while driver mutations were more common in colorectal and endometrial cancers. The overall and driver mutation rate was significantly lower for breast cancer than the mutation rates for colorectal and endometrial carcinoma, whereas amplification rates were slightly higher (Fig. 4) . Although the significance of MMR gene amplification is unknown, this aberration has not been associated with gene product inactivation. Further breakdown of genetic alterations for each tumor type and suggests a relatively low rate of driver mutations in breast cancers compared to the MMR-driven cancer types (Fig. 5) .
DISCUSSION
Immunotherapy works by allowing the immune system to identify and eradicate tumor cells. Many malignancies mount an effective defense against host immunity by expressing ligands for checkpoint receptors (eg, PD-L1, IM3, TIGIT, LAG3, VISTA) and other immunomodulatory molecules (arginase, indoleamine 2,3-dioxygenase, TGF-b, IL-10, etc.) that dampen antitumoral response; immunotherapies circumvent these defenses, allowing cytotoxic T cells, helper T cells, and NK cells to proliferate and access otherwise "cloaked" or immunologically nonsurveilled tumors. [3] [4] [5] [7] [8] [9] Central to the effectiveness of immunotherapy, thus, is a tumor's ability to invoke an immune response. This explains why CD8 + T-cell infiltration is considered a potential marker of immunotherapeutic vulnerability and, likewise, why low-grade tumors are often poor candidates for immunotherapy treatments: in order to be identified by the immune system, a malignancy must diverge significantly from what the immune system recognizes as normal self. 3, 6 Tumors attract immune attention by presenting novel antigens that are sufficiently different from normal, known as neoantigens. MMR deficiency allows for a rapid accumulation of neoantigens and explains why this molecular feature has been reproducibly linked to tumoral PD-L1 expression and immunotherapeutic response. [16] [17] [18] [19] 24, 25 However, MMR deficiency is not the only mechanism by which a tumor can rapidly accrue neoantigens, and perhaps ought not to be considered a comprehensive measure of potential immunotherapeutic vulnerability, particularly in tissues where it is a minor driver of carcinogenesis. MMR deficiency is exceedingly rare in nonsmall cell lung carcinomas (< 1%) 19 ,26 yet a significant subset of these tumors show durable responses to PD-1/ PD-L1 inhibition. 1, 3, 6 Of particular relevance in breast carcinoma, BRCA mutations have been associated with high neoantigen loads as well as elevated PD-L1 expression. [27] [28] [29] Like MMR-deficient cancers, BRCAmutated malignancies are typified by high-grade and robust tumor-infiltrating lymphocytes, emphasizing their genetic variability and propensity to produce novel mutations and divergent clones. 27, [30] [31] [32] Notably, although BRCA-mutated breast carcinomas were frequently PD-L1 + in the prior series form our institution, rates of PD-L1 positivity were not significantly greater than their BRCA-negative, triple-negative counterparts (50% vs. 43%, P = 1.0); however, numbers were limited. 21, 33 In contrast to BRCA mutations, MMR deficiency is an uncommon contributor to breast cancer pathogenesis. Less than 1% of all breast cancers and ∼2% of triplenegative breast carcinomas demonstrate MMR dysfunction in prior analyses. 19, 20 The current MMR testing by microarray and by TCGA analysis of breast cancer both yielded corroborative results. Utilization of MMR testing as the gateway for anti-PD-1/anti-PD-L1 therapy eligibility in breast cancer patients is therefore likely to result in considerable unnecessary testing expense if uninformed by pathologic factors such as tumor grade, hormone receptor/HER2 expression, and BRCA mutations status. Furthermore, it may miss patients who could be viable immunotherapeutic candidates as alternate mechanisms of neoantigen production are well-known in breast cancer, and the rates of PD-L1 expression exceed rates of MMR deficiency in this organ system (∼12% vs. <1%), particularly among triple-negative cancers for which additional therapeutic options are most needed (32% vs. 2%). Our results suggest that (1) MMR testing will only be Existing clinical trial data on the value of therapies targeting PD-1/PD-L1 in breast cancer is mixed. The landmark trials for PD-1 inhibition in breast cancer include Keynote-012, Keynote-86, Keynote-173, and the atezolizumab/nab-paclitaxel study led by Adams et al. [34] [35] [36] [37] There is also data from the ECHO-202 study of pembrolizumab plus epacadostat as well as recent Avelumab study presented at San Antonio Breast Cancer Symposium. 38, 39 The Keynote-173 study combining pembrolizumab with neoadjuvant chemotherapy achieved an 80% pathologic complete response rate in triple-negative breast cancer which was the highest response rate reported for such a trial to date. The response rates in metastatic breast cancer for PD-1 inhibitors ranged from 2% to 67% depending upon patient selection and study size/setting. Responses to PD-1 inhibitors in ER + disease have been reported, but response rates appear generally lower than triple-negative breast cancer. For example, the Javelin study reported a 2.8% response rate.
In the very earliest trials of PD-1 inhibitors in breast cancer (ie, Keynote-012), PD-L1 positivity was an eligibility requirement, but after controversy arose regarding the predictive reliability of PD-L1 immunohistochemical testing, most of the more recent trials of PD-1 inhibitors in breast cancer have collected data on PD-L1 status after enrollment, but have not used PD-L1 status as an entry criterion. Likewise, pathologic variables such as grade, BRCA status, MMR status and tumor-infiltrating lymphocytes have not been used, for inclusion in breast cancer trials. It remains unclear how well various checkpoint inhibitors will perform in more selected populations of breast cancer patients.
A final caution regarding the use of MMR to guide immunotherapeutic access in breast cancer patients is the ethical and genetic counseling quandary presented by deficient results. In the colon and endometrium, the majority of MMR-deficient results are attributable to somatic hypermethylation at the MLH1 promoter, which requires molecular confirmation. A significant proportion of the remaining unmethylated cases bear germline mutations compatible with a diagnosis of Lynch syndrome. [40] [41] [42] Identification of MMR loss therefore obligates the pathologist and clinician to consider further molecular and genetic testing to ascertain whether the patient and her family carry an increased cancer risk. Routine screening with MMR immunohistochemistry and the molecular testing and genetic counseling it can trigger are, however, clinically justified and cost-effective in the colon and endometrium because Lynch syndrome is relatively common in this setting and confirming a germline mutation can lead to detection and prevention of a large number of other malignancies. [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] Blanket MMR testing is much more problematic in the breast, where there is no strong, reproducible association with Lynch syndrome. 52, 56, 57 The complexities of expanding MMR testing are amplified by the fact that these immunohistochemical stains can show only focal and patchy expression, as evidenced by 2 cases in this series which demonstrated an apparent loss on tissue microarray cores but which were subsequently shown to be intact on whole sections. Furthermore, the stains can be difficult to interpret, particularly without experience: using interpretive criteria designed for Lynch syndrome screening, diagnosis of loss requires complete negativity of all tumor nuclei in the presence of intact stromal and/or lymphocyte control staining. This seems simple enough in theory, but practice presents many difficult cases with faint focal staining interpreted as deficient by the inexperienced eye, but which prove microsatellite stable and free of both heritable and somatic gene mutations on further testing. 43 Furthermore, the significance of partial loss patterns when screening cases for potential immunotherapeutic response remains wholly unclear. It is notable that PD-L1 was entirely negative in cases with partial loss patterns in this series (eg, the 2 ER + cases which appeared deficient on TMA, but which shows zones of intact staining on whole sections). One could argue that microsatellite instability testing is an attractive alternative but this test presents its own complexities including increased cost, lower sensitivity than MMR immunohistochemistry, and a requirement for adjacent normal tissue (rarely an option on biopsy samples). 43 Furthermore, this is a send-out test for most facilities which significantly increases turn-around time.
The flurry of clinical interest surrounding MMR status as a marker of immunotherapeutic candidacy stems, in part, from the failings of PD-L1 immunohistochemistry in this arena. Although tumor cell expression of high level PD-L1 has correlated cleanly with response to anti-PD-1/ anti-PD-L1 therapy in some studies, in others the association is less robust and vacillates depending upon the cutoff for positivity. 3, 12, 13 Breast cancer trials specifically correlating response to anti-PD-1/anti-PD-L1 therapies with PD-L1 expression thresholds are needed to determine whether PD-L1 immunohistochemistry proves-as it has in non-small cell lung carcinoma-to be an additive biomarker in the setting.
A critical limitation of this study-and indeed, in much of the literature attempting to identify biomarkers of immunotherapeutic response-is its relative myopia. PD-L1 and MMR status are players in an exquisitely complex immune interplay that involves an array of other variables such as tumor-infiltrating cytotoxic T cells, additional checkpoint molecules (such as cytotoxic T-lymphocyte-associated protein 4), and immune modulatory enzymes that can interfere with T cell function (such as indoleamine 2,3-dioxygenase). It may prove that the imperfections of PD-L1 immunohistochemistry in predicting therapeutic response derive less from intrinsic frailties in the assay and more from the coexistence of other factors that limit the immune system's ability to appropriately dismantle a tumor even after it has shed the PD-L1 cloak. The same limitations are likely to apply to MMR testing: despite the initial promise, the complexity of the immune milieu suggests that this test is unlikely to provide all the answers, particularly in the breast and other sites where it is a minor contributor to carcinogenesis. Further studies addressing the myriad other components of the antitumoral immune response-and tumoral defenses against them-are needed in the breast and elsewhere.
In summary, these data confirm that MMR deficiency is extremely uncommon in breast carcinoma. They also demonstrate that the rare MMR-deficient breast cancers identified are hormone receptor-negative and PD-L1 + , suggesting that the presence of these pathologic variables may represent the most appropriate initial screen for immunotherapeutic candidacy given the low yield of MMR testing in this site. This algorithm is also attractive because MMR testing has increased cost relative to PD-L1 immunohistochemistry. Furthermore, this approach will minimize unnecessary concern regarding equivocal MMR results in patients for whom genetic counseling and germline testing are unlikely to be relevant. 
